Algernon Pharmaceuticals Inc.

OTC: AGNPF · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCCIK 0001642178Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 33

v0.1 · 5/100 weight · pillars only

↑ listing tenure, Altman-Z · ↓ workforce scale, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-08-26

Market cap

$1.7M

as of 2026-08-26

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Algernon Pharmaceuticals Inc.’s financial profile?

Algernon Pharmaceuticals Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Restart Life Sciences Corp.——1933 Industries Inc.——Shuttle Pharmaceuticals Holdings, Inc.——Kelyniam Global, Inc.——Stemsation International, Inc.——Somatic Systems, Inc.——

Key facts

CEOChristopher J. Moreau

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeOTC: AGNPF

Employees5

IPO date2016-03-11

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.